Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 110, Issue 11, Pages 1695-1702Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI200216445
Keywords
-
Categories
Funding
- Medical Research Council [MC_U120074271] Funding Source: researchfish
- Medical Research Council [MC_U120074271] Funding Source: Medline
Ask authors/readers for more resources
Familial hypercholesterolemia is an autosomal dominant disorder with a gene-dosage effect that is usually caused by mutations in the LDL receptor gene that disrupt normal clearance of LDL. In the homozygous form, it results in a distinctive clinical phenotype, characterized by inherited hypercholesterolemia, cholesterol deposition in tendons, and severe premature coronary disease. We described previously two families with autosomal recessive hypercholesterolemia that is not due to mutations in the LDL receptor gene but is characterized by defective LDL receptor-dependent internalization and degradation of LDL by transformed lymphocytes from the patients. We mapped the defective gene to chromosome 1p36 and now show that the disorder in these and a third English family is due to novel mutations in ARHI, a newly identified gene encoding an adaptor-like protein. Cultured skin fibroblasts from affected individuals exhibit normal LDL receptor activity, but their monocyte-derived macrophages are similar to transformed lymphocytes, being unable to internalize and degrade LDL. Retroviral expression of normal human ARM restores LDL receptor internalization in transformed lymphocytes from an affected individual, as demonstrated by uptake and degradation of I-125-labeled LDL and confocal microscopy of cells labeled with anti-LDL-receptor Ab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available